Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Gross Profit (2016 - 2025)

Immucell's Gross Profit history spans 16 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 2.77% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $11.4 million, up 44.13%, while the annual FY2025 figure was $11.4 million, 44.13% up from the prior year.
  • Gross Profit reached $2.9 million in Q4 2025 per ICCC's latest filing, up from $2.4 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $3.4 million in Q1 2025 to a low of $300775.0 in Q1 2023.
  • Average Gross Profit over 5 years is $2.0 million, with a median of $2.1 million recorded in 2021.
  • Peak YoY movement for Gross Profit: plummeted 90.31% in 2023, then surged 663.15% in 2024.
  • A 5-year view of Gross Profit shows it stood at $2.6 million in 2021, then crashed by 61.25% to $992176.0 in 2022, then increased by 27.69% to $1.3 million in 2023, then soared by 123.51% to $2.8 million in 2024, then rose by 2.77% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Gross Profit are $2.9 million (Q4 2025), $2.4 million (Q3 2025), and $2.8 million (Q2 2025).